RxDoctor Payments Data

Sarinah Brown, APRN

Psychiatric/Mental Health · Hanover, MANPI 1346780145

Payments from drug & device makers

$3,387in general payments, 2019–2025

Across 159 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$848
  • AbbVie$571
  • Corium, LLC$226
  • Otsuka America Pharmaceutical, Inc.$196
  • Alkermes, Inc.$193
  • plus $340 from 7 others

What the payments were for

  • Food & beverage$3,34099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,387 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$55,876
Medicare patients
39
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine16$118,223
Lamotrigine ErLamotrigine18$4,067
Duloxetine Hcl26$1,630
Aripiprazole15$1,600
Olanzapine32$1,214
Bupropion XlBupropion Hcl50$1,041
Mirtazapine19$752
Quetiapine Fumarate29$646
Methylphenidate ErMethylphenidate Hcl12$531
Methylphenidate Hcl25$490
Lamotrigine41$442
Divalproex Sodium ErDivalproex Sodium22$352
Escitalopram Oxalate21$206
Risperidone13$195
Venlafaxine Hcl ErVenlafaxine Hcl19$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$848$118,22316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Hanover

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →